In an initial attempt to transform the highly active AngIV analog, Nle 1 -AngIV, into an effective drug, we evaluated the procognitive activity of a series of C-terminal truncated peptides derived from Nle 1 -AngIV (Benoist et al., 2011)
Liver TG and cholesterol content
Our governance model includes: Prescribing restricted to Dr Nirusha Kumaran and Dr Tasnim Elghandy, both holding valid certification in peptide therapy Quarterly clinical audit of outcomes, adverse events, and adherence Documented discontinuation criteria for every active protocol An active adverse event registry and clinical KPI tracking No prescribing in cases of active malignancy, pregnancy, or severe psychiatric illness This level of institutional rigour is what separates physician-led peptide therapy from the commercially driven, under-regulated alternatives that exist elsewhere in the market
Menzies et al., 2008)
The peptide demonstrates broad regenerative properties across multiple tissue types
Naturally inspired transformation
